P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT

Neuroscience Letters

Volumn 493, Issue 3, 2011, Pages 127-130

  Viikki, Merja ^a,b   Kampman, Olli ^a,c   Anttila, Sami ^a,d   Illi, Ari ^e   Setälä Soikkeli, Eija ^d   Huuhka, Martti ^d   Mononen, Nina ^d   Lehtimäki, Terho ^d   Leinonen, Esa ^a,d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Tampere Health Centre   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e KANTA HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

489C>T; ECT; Gln460Arg; H155Y; His155Tyr; Polymorphism; Q460R; Rs208294; Rs2230912; Treatment response; Treatment resistant depression

Indexed keywords

PURINERGIC P2X7 RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ELECTROCONVULSIVE THERAPY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; REMISSION;

ADULT; AGED; ARGININE; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; GLUTAMINE; HISTIDINE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2X7; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TYROSINE;

EID: 79952898989     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.02.023     Document Type: Article

References (40)

1. Anderson C.M., Nedergaard M. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends Neurosci. 2006, 29:257-262.
2. Anttila S., Huuhka K., Huuhka M., Rontu R., Mattila K.M., Leinonen E., Lehtimäki T. Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression. J. Neural Transm. 2007, 114:461-468.
3. Barden N., Harvey M., Gagné B., Shink E., Tremblay M., Raymond C., Labbé M., Villeneuve A., Rochette D., Bordeleau L., Stadler H., Holsboer F., Müller-Myhsok B. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141B:374-382.
4. Basso A.M., Bratcher N.A., Harris R.R., Jarvis M.F., Decker M.W., Rueter L.E. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav. Brain Res. 2009, 198:83-90.
5. Burnstock G. Purinergic signalling: past, present and future. Braz. J. Med. Biol. Res. 2009, 42(1):3-8. Jan.
6. Cabrini G., Falzoni S., Forchap S.L., Pellegatti P., Balboni A., Agostini P., Cuneo A., Castoldi G., Baricordi O.R., Di Virgilio F. A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J. Immunol. 2005, 175:82-89.
7. Chessell I.P., Hatcher J.P., Bountra C., Michel A.D., Hughes J.P., Green P., Egerton J., Murfin M., Richardson J., Peck W.L., Grahames C.B., Casula M.A., Yiangou Y., Birch R., Anand P., Buell G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005, 114:386-396.
8. Denlinger L.C., Coursin D.B., Schell K., Angelini G., Green D.N., Guadarrama A.G., Halsey J., Prabhu U., Hogan K.J., Bertics P.J. Human P2X7 pore function predicts allele linkage disequilibrium. Clin. Chem. 2006, 52:995-1004.
9. Deuchars S.A., Atkinson L., Brooke R.E., Musa H., Milligan C.J., Batten T.F., Buckley N.J., Parson S.H., Deuchars J. Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J. Neurosci. 2001, 21:7143-7152.
10. Erhardt A., Lucae S., Unschuld P.G., Ising M., Kern N., Salyakina D., Lieb R., Uhr M., Binder E.B., Keck M.E., Müller-Myhsok B., Holsboer F. Association of polymorphisms in P2RX7 and CaMKKb with anxiety disorders. J. Affect. Disord. 2007, 101:159-168.
11. Green E.K., Grozeva D., Raybould R., Elvidge G., Macgregor S., Craig I., Farmer A., McGuffin P., Forty L., Jones L., Jones I., O'Donovan M.C., Owen M.J., Kirov G., Craddock N. P2RX7: A bipolar and unipolar disorder candidate susceptibility gene?. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, 150B:1063-1069.
12. Grigoroiu-Serbanescu M., Herms S., Mühleisen T.W., Georgi A., Diaconu C.C., Strohmaier J., Czerski P., Hauser J., Leszczynska-Rodziewicz A., Jamra R.A., Babadjanova G., Tiganov A., Krasnov V., Kapiletti S., Neagu A.I., Vollmer J., Breuer R., Rietschel M., Nöthen M.M., Cichon S., Propping P., Nöthen M.M., Cichon S. Variation in P2RX7 candidate gene (rs2230912) is not associated with bipolar I disorder and unipolar major depression in four European samples. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, 150B:1017-1021.
13. Gu B.J., Zhang W., Worthington R.A., Sluyter R., Dao-Ung P., Petrou S., Barden J.A., Wiley J.S. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J. Biol. Chem. 2001, 276:11135-11142.
14. Gu B.J., Sluyter R., Skarratt K.K., Shemon A.N., Dao-Ung L.P., Fuller S.J., Barden J.A., Clarke A.L., Petrou S., Wiley J.S. An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J. Biol. Chem. 2004, 279:31287-31295.
15. Hejjas K., Szekely A., Domotor E., Halmai Z., Balogh G., Schilling B., Sarosi A., Faludi G., Sasvari-Szekely M., Nemoda Z. Association between depression and the Gln460Arg polymorphism of P2RX7 gene: a dimensional approach. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, 150B:295-299.
16. Illes P., Ribeiro J.A. Neuronal P2 receptors of the central nervous system. Curr. Top. Med. Chem. 2004, 4:831-838.
17. Illi A., Setälä-Soikkeli E., Viikki M., Poutanen O., Huhtala H., Mononen N., Lehtimäki T., Leinonen E., Kampman O. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
18. Idzko M., Panther E., Bremer H.C., Sorichter S., Luttmann W., Virchow C.J., Di Virgilio F., Herouy Y., Norgauer J., Ferrari D. Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br. J. Pharmacol. 2003, 138:1244-1250.
19. Leonard B.E. The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:767-780.
20. Lodge N.J., Li Y.W. Ion channels as potential targets for the treatment of depression. Curr. Opin. Drug Discov. Dev. 2008, 11:633-641.
21. Lucae S., Salyakina D., Barden N., Harvey M., Gagné B., Labbé M., Binder E.B., Uhr M., Paez-Pereda M., Sillaber I., Ising M., Brückl T., Lieb R., Holsboer F., Müller-Myhsok B. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet. 2006, 15:2438-2445.
22. Maes M., Song C., Lin A.H., Bonaccorso S., Kenis G., De Jongh R., Bosmans E., Scharpé S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999, 20:370-379.
23. McQuillin A., Bass N.J., Choudhury K., Puri V., Kosmin M., Lawrence J., Curtis D., Gurling H.M. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol. Psychiatry 2009, 14:614-620.
24. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
25. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
26. Nagy G., Ronai Z., Somogyi A., Sasvari-Szekely M., Rahman O.A., Mate A., Varga T., Nemoda Z. P2RX7 Gln460Arg polymorphism is associated with depression among diabetic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1884-1888.
27. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82:1013-1067.
28. Parvathenani L.K., Tertyshnikova S., Greco C.R., Roberts S.B., Robertson B., Posmantur R. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem. 2003, 278:13309-13317.
29. Roger S., Mei Z.Z., Baldwin J.M., Dong L., Bradley H., Baldwin S.A., Surprenant A., Jiang L.H. Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J. Psychiatr. Res. 2010, 44:347-355.
30. Shemon A.N., Sluyter R., Fernando S.L., Clarke A.L., Dao-Ung L.P., Skarratt K.K., Saunders B.M., Tan K.S., Gu B.J., Fuller S.J., Britton W.J., Petrou S., Wiley J.S. A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J. Biol. Chem. 2006, 281:2079-2086.
31. Skaper S.D., Debetto P., Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2010, 24:337-345.
32. Sluyter R., Barden J.A., Wiley J.S. Detection of P2X purinergic receptors on human B lymphocytes. Cell. Tissue Res. 2001, 304:231-236.
33. Słuzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 1995, 762:474-476.
34. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, January 21 (Epub ahead of print).
35. Sun C., Chu J., Singh S., Salter R.D. Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function. Purinergic Signal 2010, 6:31-45.
36. Surprenant A., North R.A. Signaling at purinergic P2X receptors. Annu. Rev. Physiol. 2009, 71:333-359.
37. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 1996, 215:201-204.
38. Viikki M., Anttila S., Kampman O., Illi A., Huuhka M., Setälä-Soikkeli E., Mononen N., Lehtimäki T., Leinonen E. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci. Lett. 2010, 47:105-108.
39. Wiley J.S., Dao-Ung L.P., Li C., Shemon A.N., Gu B.J., Smart M.L., Fuller S.J., Barden J.A., Petrou S., Sluyter R. An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J. Biol. Chem. 2003, 278:17108-17113.
40. Wirkner K., Köfalvi A., Fischer W., Günther A., Franke H., Gröger-Arndt H., Nörenberg W., Madarász E., Vizi E.S., Schneider D., Sperlágh B., Illes P. Supersensitivity of P2X receptors in cerebrocortical cell cultures after in vitro ischemia. J. Neurochem. 2005, 95:1421-1437.